Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.

James M Martin Elizabeth A HandorfAlberto J MonteroLori J Goldstein

Published in: The oncologist (2022)

While prospective data are needed, analysis of real-world data suggests a survival benefit for continuation of a CDK4/6i beyond frontline progression for patients with HR+/Her2- MBC.

Keyphrases

electronic health record
big data
cell cycle
artificial intelligence
deep learning
combination therapy
free survival